KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $3.1 million.

  • Recursion Pharmaceuticals' Short-term Investments rose 10167.2% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 10167.2%. This contributed to the annual value of $3.0 million for FY2024, which is 575.67% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Short-term Investments stood at $3.1 million, which was up 10167.2% from $3.1 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Short-term Investments high stood at $231.4 million for Q4 2021, and its period low was $1.3 million during Q4 2022.
  • Its 5-year average for Short-term Investments is $32.0 million, with a median of $3.1 million in 2025.
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 1147230.0% in 2021, then tumbled by 9944.7% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Short-term Investments (Quarter) stood at $231.4 million in 2021, then crashed by 99.45% to $1.3 million in 2022, then skyrocketed by 152.42% to $3.2 million in 2023, then fell by 5.76% to $3.0 million in 2024, then grew by 2.99% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.1 million for Q2 2025, and $3.1 million during Q1 2025.